Photo of Boris Gershman,  MD

Boris Gershman, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-3739


bgershma@bidmc.harvard.edu

Boris Gershman, MD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Assistant Professor, Surgery, Harvard Medical School
  • Urologist, Surgery, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

My research interests focus on two overarching areas. First, I am interested in investigating the comparative effectiveness of treatments for urologic cancers. Although randomized clinical trials are the preferred study design to evaluate the comparative effectiveness of interventions, there are very few trials comparing surgical treatments within urologic oncology, in part due to the difficulty of conducting surgical trials. To address such fundamental evidence gaps, I am interested in the application of two novel observational research methods when clinical trial evidence is limited: emulation of target clinical trials using observational datasets, and transportation of inferences from competed clinical trials to “real-world” patient populations.

My other research interest is the development of deep learning methods to improve the diagnosis and risk-stratification of urologic cancers. Together with collaborators from Brown University, we have developed deep learning methods to improve the histopathologic diagnosis and Gleason grading of prostate cancer biopsy specimens. Additional work is ongoing to extend these efforts to other prediction tasks.

Publications

Powered by Harvard Catalyst
  • Monfared S, Fleishman A, Korets R, Chang P, Wagner A, Bubley G, Kaplan I, Olumi AF, Gershman B. The impact of pretreatment PSA on risk stratification in men with Gleason 6 prostate cancer: Implications for active surveillance. Urol Oncol 2021. PubMed
  • Reitblat C, Fleishman A, Kaplan IA, Stensland KD, D'Amico AV, Olumi AF, Wagner AA, Chang PK, Kim SP, Korets R, Gershman B. Radical prostatectomy versus external beam radiation therapy for high-grade, clinically localized prostate cancer: Emulation of a target clinical trial. Urol Oncol 2021. PubMed
  • Rodrigues Pessoa R, Mueller AC, Boxley P, Flaig TW, Piper C, Konety B, Yu JB, Gershman B, Kukreja J, Kim SP. Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer. Urol Oncol 2021. PubMed
  • Rodrigues Pessoa R, Morrison JC, Konety B, Gershman B, Maroni P, Kukreja JB, Cost N, Flaig T, Kessler E, Sharma P, Kim SP. National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy. Urol Oncol 2021. PubMed
  • Unadkat P, Fleishman A, Olumi AF, Wagner A, Chang P, Kim SP, Korets R, Gershman B. Contemporary Incidence and Predictors of Occult Inguinal Lymph Node Metastases in Men with Clinically Node-Negative (cN0) Penile Cancer. Urology 2021. PubMed
  • Reitblat C, Bellmunt J, Gershman B. Management of Clinically Regional Node-Positive Urothelial Carcinoma of the Bladder. Curr Oncol Rep 2021; 23:24. PubMed
  • Chandrasekar T, Boorjian SA, Capitanio U, Gershman B, Mir MC, Kutikov A. Collaborative Review: Factors Influencing Treatment Decisions for Patients with a Localized Solid Renal Mass. Eur Urol 2021. PubMed
  • Reitblat C, Bain PA, Porter ME, Bernstein DN, Feeley TW, Graefen M, Iyer S, Resnick MJ, Stimson CJ, Trinh QD, Gershman B. Value-Based Healthcare in Urology: A Collaborative Review. Eur Urol 2021. PubMed
  • Puneet K, Tilburt JC, Volk RJ, Bennett CL, Qureshi Z, Gershman B, Sedlacek HM, Kim SP. Do radiation oncologists and urologists endorse decision aids for active surveillance of low-risk prostate cancer: Results from a national survey. Eur J Cancer Care (Engl) 2021; 30:e13301. PubMed
  • Golijanin B, Gershman B, De Souza A, Kott O, Carneiro BA, Mega A, Golijanin DJ, Amin A. p53 Expression, Programmed Death Ligand 1, and Risk Factors in Urinary Tract Small Cell Carcinoma. 2021; 11:651754. PubMed
  • Morrison JC, Gershman B, Konety B, Cost N, Kim SP. Centralization of Health Care to Facilitate Greater Use of Nephron-Sparing Surgery for Localized Renal Tumors: Identifying Appropriate Health Care Delivery. Ann Surg Oncol 2020; 27:1735-1736. PubMed
Member Summary Video